Table 1.
Baseline clinical characteristics by tumor type
| Characteristic | NSCLC (%) | Melanoma (%) | Renal (%) | Other (%) |
|---|---|---|---|---|
| No., n = 812 | 204 (25.1) | 456 (56.2) | 141 (17.4) | 11 (1.3) |
| Age, median (range), y | 68 (43-85) | 67 (26-94) | 67 (43-86) | 68 (61-81) |
| Gender | ||||
| Female | 73 (35.8) | 184 (40.4) | 31 (22) | 1 (9.1) |
| Male | 131 (64.2) | 272 (59.6) | 110 (78) | 10 (90.9) |
| ECOG-PS | ||||
| 0-1 | 181 (88.7) | 439 (96.3) | 134 (95) | 11 (100) |
| ≥2 | 22 (10.8) | 16 (3.5) | 7 (5) | 0 |
| Unknown | 1 (0.5) | 1 (0.2) | 0 | 0 |
| Smoking status | ||||
| Current | 61 (29.9) | 59 (12.9) | 15 (10.6) | 3 (27.3) |
| Former | 128 (62.7) | 119 (26.1) | 72 (51.1) | 6 (54.5) |
| Never | 15 (7.4) | 278 (61) | 54 (38.3) | 2 (18.2) |
| Treatment setting | ||||
| First line | 138 (67.6) | 232 (50.9) | 8 (5.7) | 2 (18.2) |
| ≥ Second line | 66 (32.4) | 75 (16.4) | 133 (94.3) | 9 (81.8) |
| Adjuvant | 0 | 149 (32.7) | 0 | 0 |
| No. of metastatic sitesa | ||||
| <2 | 61 (29.9) | 86 (28) | 23 (16.3) | 1 (9.1) |
| ≥2 | 119 (58.3) | 180 (58.6) | 111 (78.7) | 9 (81.8) |
| Unknown | 24 (11.8) | 41 (13.4) | 7 (5) | 1 (9.1) |
| Surgeryb | ||||
| Yes | 34 (16.7) | 393 (86.2) | 121 (85.8) | 7 (63.6) |
| No | 170 (83.3) | 63 (13.8) | 20 (14.2) | 4 (36.4) |
| Concomitant radiotherapyc | ||||
| Yes | 37 (18.1) | 85 (18.6) | 33 (23.4) | 1 (9.1) |
| No | 166 (81.4) | 370 (81.1) | 107 (75.9) | 10 (90.9) |
| Unknown | 1 (0.5) | 1 (0.3) | 1 (0.7) | 0 |
| Type of ICI | ||||
| Pembrolizumab | 169 (82.8) | 87 (19.1) | 5 (3.5) | 11 (100) |
| Upfront CD | 138 (67.6) | 62 (13.6) | 3 (2.1) | 8 (72.7) |
| Upfront ED | 31 (15.2) | 25 (5.5) | 2 (1.4) | 3 (27.3) |
| Nivolumab | 35 (17.2) | 369 (80.9) | 136 (96.5) | 0 |
| Upfront CD | 34 (16.7) | 208 (45.6) | 97 (68.8) | 0 |
| Upfront ED | 1 (0.5) | 161 (35.3) | 39 (27.7) | 0 |
| irAEs onset | ||||
| Yes | 95 (46.6) | 252 (55.3) | 60 (42.6) | 4 (36.4) |
| No | 109 (53.4) | 204 (44.7) | 81 (57.4) | 7 (63.6) |
a
Percentage calculated on the number of patients with metastatic cancer. CD = canonical interval dosing; ECOG-PS = Eastern Operative Oncology Group Performance Score; ED = extended interval dosing; ICI = immune checkpoint inhibitor; irAEs = immune-related adverse events; NSCLC = non-small cell lung cancer.
b
Surgery refers to resection of primitive tumor or metastatic site or both.
c
Radiotherapy concomitant to ICIs refers to primitive tumor, metastatic site, or both.